Deuterated morphinan compounds for treating agitation

Patent metadata

Field	Value
Publication number	US-2018243289-A1
Application number	US-201615748804-A
Country	US
Kind code	A1
Filing date	Jul 29, 2016
Priority date	Jul 30, 2015
Publication date	Aug 30, 2018
Grant date	—

Abstract

This invention relates to methods of treating agitation comprising administering a morphinan compound or a pharmaceutically acceptable salt thereof. This invention also provides the use in methods of treating agitation and related disorders with such a morphinan compound in combination with quinidine, or pharmaceutically acceptable salt of either or both thereof.

First claim

1 . A method of treating agitation comprising administering to a subject in need thereof, an effective amount of a compound of Formula I:

or a pharmaceutically acceptable salt thereof, wherein R 1 is an ethyl group optionally substituted by one to five deuterium atoms; and R 2 is a methyl group optionally substituted by one to three deuterium atoms; provided that at least one deuterium atom is present at either R 1 or R 2 , and a pharmaceutically acceptable carrier.

2 . The method of claim 1 , wherein R 1 is —CH 2 CH 3 , —CD 2 CH 3 , —CH 2 CD 3 , or —CD 2 CD 3 ; and R 2 is —CH 3 or —CD 3 .

3 . The method of claim 1 , wherein for the compound of Formula I, any atom not designated as deuterium is present at its natural isotopic abundance.

4 . The method of claim 3 , wherein the compound of Formula I is a compound selected from the table:

Compound No.
R 1
R 2

100
—O—CD 2 CD 3
CD 3

101
—O—CD 2 CH 3
CD 3

102
—O—CH 2 CH 3
CD 3

103
—O—CH 2 CD 3
CD 3

104
—O—CD 2 CD 3
CH 3

105
—O—CD 2 CH 3
CH 3

106
—O—CH 2 CD 3
CH 3

or a pharmaceutically acceptable salt thereof.

5 . The method of claim 3 , further comprising administering to the subject an amount of quinidine, or a pharmaceutically acceptable salt thereof, wherein the amount of quinidine, or a pharmaceutically acceptable salt thereof, is in the range of 1 mg/day to 40 mg/day.

6 . The method of claim 5 , wherein the amount of the compound of Formula I is in the range of 5 mg/day to 250 mg/day.

7 . The method of claim 1 , wherein the agitation is associated with a disorder selected from the group consisting of Alzheimer's disease, a degenerative neurological disorder, a mood disorder, substance abuse withdrawal, selective serotonin reuptake inhibitor (SSRI) withdrawal, withdrawal from benzodiazepines, withdrawal from drugs useful for the treatment of attention deficit disorder (ADD) and attention deficit hyperactive disorder (ADHD), traumatic brain injury, terminal illness, post-operative agitation, post-anesthetic agitation, Reye's syndrome and a pediatric disorder.

8 . The method of claim 7 wherein the degenerative neurological disorder is Parkinson's disease or Huntington's disease.

9 . The method of claim 7 wherein the mood disorder is depression, dysthymia, schizophrenia or bipolar disorder.

10 . The method of claim 7 wherein the SSRI is selected from fluoxetine, fluvoxamine, citalopram, escitalopram, paroxetine and sertraline

11 . The method of claim 7 wherein the drug useful for the treatment of ADD or ADHD is selected from methamphetamine hydrochloride, methylphenidate hydrochloride, dextroamphetamine sulfate, mixed amphetamine salts, pemoline, dexmethylphenidate hydrochloride, and lisdexamfetamine mesilate.

12 . The method of claim 7 wherein the pediatric disorder is depression, attention deficit disorder, oppositional defiant disorder, or separation anxiety disorder.

13 . The method of claim 7 , wherein the agitation is associated with Alzheimer's disease.

14 . The method of claim 7 , wherein the agitation is associated with traumatic brain injury.

15 . A method of treating a disease or disorder selected from the group consisting of diabetes, epilepsy, and depression, comprising administering to a subject in need thereof, an effective amount of a compound of Formula I:

or a pharmaceutically acceptable salt thereof, wherein R 1 is an ethyl group optionally substituted by one to five deuterium atoms; and R 2 is a methyl group optionally substituted by one to three deuterium atoms; provided that at least one deuterium atom is present at either R 1 or R 2 ;
quinidine or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

16 . The method of claim 15 , wherein R 1 is —CH 2 CH 3 , —CD 2 CH 3 , —CH 2 CD 3 , or —CD 2 CD 3 ; and R 2 is —CH 3 or —CD 3 .

17 . The method of claim 15 , wherein for the compound of Formula I, any atom not designated as deuterium is present at its natural isotopic abundance.

18 . The method of claim 17 , wherein the compound of Formula I is a compound selected from the table:

Compound No.
R 1
R 2

100
—O—CD 2 CD 3
CD 3

101
—O—CD 2 CH 3
CD 3

102
—O—CH 2 CH 3
CD 3

103
—O—CH 2 CD 3
CD 3

104
—O—CD 2 CD 3
CH 3

105
—O—CD 2 CH 3
CH 3

106
—O—CH 2 CD 3
CH 3

or a pharmaceutically acceptable salt thereof.

19 . The method of claim 15 , wherein the amount of the compound of Formula I, or a pharmaceutically acceptable salt thereof, is in the range of 5 mg/day to 500 mg/day, and the amount of quinidine, or a pharmaceutically acceptable salt thereof, is in the range of 1 mg/day to 40 mg/day.

20 . The method of claim 15 , wherein the amount of the compound of Formula I, or a pharmaceutically acceptable salt thereof, is in the range of 5 mg/day to 250 mg/day and the amount of quinidine, or a pharmaceutically acceptable salt thereof, is in the range of 1 mg/day to 20 mg/day.

21 . The method of claim 15 , wherein the amount of the compound of Formula I, or a pharma

Assignees

• Concert Pharmaceuticals Inc

Inventors

• Tung Roger D

Classifications

• A61K31/49

  Cinchonan derivatives, e.g. quinine · CPC title

• A61K31/485 Primary

  Morphinan derivatives, e.g. morphine, codeine · CPC title

• A61P25/00

  Drugs for disorders of the nervous system · CPC title